Longer commute for cancer treatment associated with better survival

September 16, 2003

Cancer patients who travel more than 15 miles for treatment appear to survive longer than patients who live closer to their treatment center, even after controlling for factors such as disease stage and economic status, concludes a study in the September 17 issue of the Journal of the National Cancer Institute.

The study looked specifically at outcomes of phase II trials. Data from phase II trials are used to determine whether a drug is promising enough to proceed to phase III trials, which ultimately determine whether the drug is approved by the U.S. Food and Drug Administration. The finding that phase II results can be influenced by patient travel distance raises the possibility of biased conclusions about which drugs should advance to phase III evaluation.

The study, conducted by Elizabeth B. Lamont, M.D., of the Massachusetts General Hospital Cancer Center in Boston, and her colleagues at the University of Chicago, involved 110 patients with head and neck cancer who were enrolled in one of four phase II clinical trials at the University of Chicago Medical Center. The authors looked at the association between overall survival and progression-free survival and the distance from the patient's home to the treatment center.

Patients who traveled 15 or more miles for their care had one-third the risk of death of those living closer, even after adjusting for standard disease and demographic factors. Moreover, for every 10 miles that a patient traveled for care, the risk of death decreased by 3.2%. A similar pattern was seen with progression-free survival.

The authors explain that patients who are able to obtain information on treatment options and have the resources to allow them to pursue those options may have better outcomes than patients who end up at the nearest place for care, even if their diseases and treatments are the same. The authors note that more work is needed to understand what individual and social factors travel distance is mediating.

In an accompanying editorial, Stephen L. George, Ph.D., of Duke University Medical Center in Durham, N.C., examines the new findings in the context of the FDA's relatively recent accelerated approval process, which allows drugs to be approved based on results of phase II trials. He advises caution when interpreting the results of phase II trials.

"Randomized trials comparing a new regimen against a control or placebo offer the best protection against the risks of erroneous conclusions inherent in phase II trials, especially for regulatory decisions," he concludes. "Accelerated approval may provide earlier access to potentially beneficial agents, but the evidence required for granting it should not come solely from phase II trials."
-end-
Contact: Sue McGreevey, Massachusetts General Hospital, 617-724-2764, smcgreevey@partners.org; John Easton, University of Chicago, 773-702-6241, jeaston@uchicago.edu.

Editorial: Becky Levine, Duke University Medical Center, 919-684-4148, levin005@mc.duke.edu.

Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, et al. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 2003;95:1370-75.

Editorial: George SL. Selection bias, phase II trials, and the FDA accelerated approval process. J Natl Cancer Inst 2003;95:1351-2.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Cancer Patients Articles from Brightsurf:

Higher risk of death in cancer patients with COVID-19 may be due to advanced age and more pre-existing conditions, rather than cancer itself
New research presented at this this week's ESCMID Conference on Coronavirus Diseases (ECCVID, online 23-25 September) suggests that the poor outcomes and higher death rates in cancer patients with COVID-19 could be due to them generally being older and having more underlying conditions, rather than due to the cancer itself.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

The art of cancer caregiving: How art therapies benefits those caring for cancer patients
A recent Drexel University study showed coloring and open-studio art therapy benefits stressed caregivers of cancer patients.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer tissue-freezing approach may help more breast cancer patients in lower income countries
A new reusable device created by the Johns Hopkins University can help women with breast cancer in lower income countries by using carbon dioxide, a widely available and affordable gas, to power a cancer tissue-freezing probe instead of industry-standard argon.

Lots of patients with cancer, cancer survivors use but don't report complementary/alternative medicine therapies
This study used data from a nationwide survey to estimate how many patients with cancer and cancer survivors use complementary and alternative medicines (CAMS) in addition to or instead of conventional therapies, and how many don't disclose that to their physicians.

Colorectal cancer in patients with early onset is distinct from that in older patients
New research indicates that colorectal cancer diagnosed at an early age has clinical and genetic features that are different from those seen in traditional colorectal cancer diagnosed later in life.

Comparable risk of recurrent venous thromboembolism between patients with unprovoked venous thromboembolism and patients with cancer
Patients with venous thromboembolism (VTE) carry a high risk of recurrence.

Personalized cancer vaccine may increase long-term survival in patients with deadly brain cancer
An international Phase III study led by researchers at UCLA has found that a personalized GBM vaccine may increase long-term survival in some patients.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

Read More: Cancer Patients News and Cancer Patients Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.